Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results

Mazyar Shadman, John M. Burke, Jennifer Cultrera, Habte A. Yimer, Syed F. Zafar, Jamal Misleh, Subramanya S. Rao, Charles M. Farber, Aileen Cleary Cohen, Hui Yao, Adam Idoine, Qi An, Ian W. Flinn, Jeff P. Sharman

Blood Adv bloodadvances.2024015493.

https://doi.org/10.1182/bloodadvances.2024015493

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Blood Adv (2025) 9 (8): 1861–1872.

https://doi.org/10.1182/bloodadvances.2024015314

Published: 2025

Includes: Supplemental data

Journal Articles

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O’Brien, Constantine S. Tam, Lugui Qiu, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman

Blood Adv (2025) 9 (8): 1918–1926.

https://doi.org/10.1182/bloodadvances.2024014206

Published: 2025

Includes: Supplemental data

Journal Articles

The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy

Eleftheria Kampouri, Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal, Terry L Stevens-Ayers, Damian J Green, Jordan Gauthier, Mazyar Shadman, Ailyn C. Pérez-Osorio, Keith R Jerome, Wendy M Leisenring, Michael J Boeckh, Joshua A. Hill

Blood Adv bloodadvances.2024015164.

https://doi.org/10.1182/bloodadvances.2024015164

Published: 2025

Includes: Supplemental data

Journal Articles

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Mazyar Shadman, Jennifer R. Brown, Leyla Mohseninejad, Keri Yang, Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan M. O'Brien, M.D., Alessandra Tedeschi, Constantine S. Tam

Blood Adv bloodadvances.2024014523.

https://doi.org/10.1182/bloodadvances.2024014523

Published: 2025

Includes: Supplemental data

Journal Articles

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

Blood Adv bloodadvances.2024014263.

https://doi.org/10.1182/bloodadvances.2024014263

Published: 2025

Journal Articles

Consensus in CLL: global needs matter

Mazyar Shadman, Bita Fakhri, Nitin Jain

Blood Adv (2025) 9 (5): 1210–1212.

https://doi.org/10.1182/bloodadvances.2024015355

Published: 2025

Journal Articles

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Blood Adv (2025) 9 (4): 696–703.

https://doi.org/10.1182/bloodadvances.2024013640

Published: 2025

Includes: Supplemental data

Journal Articles

Development and validation of predictive models of early immune effector cell–associated hematotoxicity

Blood Adv (2025) 9 (3): 606–616.

https://doi.org/10.1182/bloodadvances.2024014455

Published: 2025

Includes: Supplemental data

Journal Articles

CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma

Priyanka A. Pophali, Joshua A. Fein, Kwang W. Ahn, Molly Allbee-Johnson, Nausheen Ahmed, Farrukh T. Awan, Shatha Farhan, Natalie S. Grover, Talal Hilal, Madiha Iqbal, Joseph Maakaron, Dipenkumar Modi, Elham Nasrollahi, Levanto G. Schachter, Craig Sauter, Mehdi Hamadani, Alex Herrera, Roni Shouval, Mazyar Shadman

Blood Adv (2024) 8 (20): 5290–5296.

https://doi.org/10.1182/bloodadvances.2024013863

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience

Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Laura Samples, Mazyar Shadman, Farrukh T. Awan, Alexandra E. Rojek, Peter A. Riedell, Madiha Iqbal, Timothy S. Fenske, Mohamed A. Kharfan-Dabaja, Sawa Ito, Mehdi Hamadani

Blood Adv (2024) 8 (13): 3528–3531.

https://doi.org/10.1182/bloodadvances.2023012255

Published: 2024

Journal Articles

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Blood Adv (2024) 8 (9): 2085–2093.

https://doi.org/10.1182/bloodadvances.2023011569

Published: 2024

Journal Articles

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic

Rahul Banerjee, Christina Poh, Alexandre V. Hirayama, Jordan Gauthier, Ryan D. Cassaday, Mazyar Shadman, Andrew J. Cowan, Brian G. Till, Damian J. Green, Hans-Peter Kiem, Ajay K. Gopal, David G. Maloney

Blood Adv (2024) 8 (4): 895–898.

https://doi.org/10.1182/bloodadvances.2023012336

Published: 2024

Journal Articles

Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Blood Adv (2024) 8 (2): 453–467.

https://doi.org/10.1182/bloodadvances.2023011287

Published: 2024

Includes: Supplemental data

Journal Articles

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

Emily C. Liang, Aya Albittar, Jennifer J. Huang, Alexandre V. Hirayama, Erik L. Kimble, Andrew J. Portuguese, Aude Chapuis, Mazyar Shadman, Brian G. Till, Ryan D. Cassaday, Filippo Milano, Hans-Peter Kiem, Stanley R. Riddell, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

Blood Adv (2023) 7 (22): 6990–7005.

https://doi.org/10.1182/bloodadvances.2023011399

Published: 2023

Includes: Supplemental data

Journal Articles

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

W. Richard Burack, Hongli Li, Diana Adlowitz, Janice M. Spence, Lisa M. Rimsza, Mazyar Shadman, Catherine M. Spier, Mark S. Kaminski, John P. Leonard, Michael L. Leblanc, Sonali M. Smith, Jonathan W. Friedberg

Blood Adv (2023) 7 (17): 5082–5090.

https://doi.org/10.1182/bloodadvances.2022009467

Published: 2023

Includes: Supplemental data

Journal Articles

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Blood Adv (2023) 7 (17): 4926–4935.

https://doi.org/10.1182/bloodadvances.2022009260

Published: 2023

Includes: Supplemental data

Journal Articles

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia

Blood Adv (2023) 7 (17): 4728–4737.

https://doi.org/10.1182/bloodadvances.2022009164

Published: 2023

Includes: Supplemental data

Journal Articles

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma

Blood Adv (2023) 7 (14): 3516–3529.

https://doi.org/10.1182/bloodadvances.2022009309

Published: 2023

Includes: Supplemental data

Journal Articles

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Blood Adv (2023) 7 (11): 2449–2458.

https://doi.org/10.1182/bloodadvances.2022009145

Published: 2023

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

Consensus in CLL: global needs matter

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Development and validation of predictive models of early immune effector cell–associated hematotoxicity

CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma

CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic

Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only